Amgen(US:AMGN) 美股IPO·2026-02-04 23:27Core Viewpoint - Amgen reported strong performance in 2025 with a 10% year-over-year growth in revenue and non-GAAP earnings per share, driven by its cholesterol-lowering drug, Leqvio, and a robust pipeline of innovative therapies [5][10][12]. Financial Performance - Total revenue for 2025 reached $36.751 billion, a 10% increase from $33.424 billion in 2024 [12]. - Product sales also grew by 10% to $35.148 billion, accounting for over 90% of total revenue [12]. - Non-GAAP net income rose to $11.837 billion, reflecting a 10% increase, with non-GAAP EPS reaching $21.84, up 10% from the previous year [12][13]. - Free cash flow for the year was $8.1 billion, supporting R&D investments and shareholder returns, with dividends per share increasing by 6% to $2.38 [13]. R&D Pipeline - Amgen invested $7 billion in R&D in 2025, focusing on four therapeutic areas: general medicine, rare diseases, inflammation, and oncology [16]. - The pipeline includes significant programs such as MariTide for chronic weight management and Repatha for cardiovascular outcomes, with multiple Phase 3 studies ongoing [24][27]. - MariTide has shown promising Phase 2 results, maintaining weight loss in patients and demonstrating safety [24][26]. Product Performance - In general medicine, Repatha achieved $3.016 billion in sales, a 36% increase, while EVENITY grew by 34% to $2.1 billion [66]. - Rare disease products UPLIZNA and TAVNEOS saw explosive growth, with UPLIZNA's sales increasing by 73% to $655 million [68]. - In the inflammation sector, TEZSPIRE's sales grew by 52% to $1.478 billion, despite declines in other products due to biosimilar competition [71]. Market Outlook - For 2026, Amgen set a revenue guidance of $37.0 billion to $38.4 billion and non-GAAP EPS of $21.60 to $23.00, reflecting confidence in core product growth and pipeline advancements [76][77]. - Key growth drivers include the clinical advancement of MariTide and Olpasiran, expansion of existing products like Repatha and TEZSPIRE, and continued growth in the rare disease segment [77]. Strategic Positioning - Amgen's 2025 performance underscores the importance of innovation and a strong pipeline in the competitive biopharmaceutical market [78]. - The company maintains a dual focus on deepening its core therapeutic areas while strategically expanding its pipeline through acquisitions and collaborations [78].